# A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

> **NCT03060850** · PHASE1 · UNKNOWN · sponsor: **Hangzhou ACEA Pharmaceutical Research Co., Ltd.** · enrollment: 184 (estimated)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** AC0010MA

## Key facts

- **NCT ID:** NCT03060850
- **Lead sponsor:** Hangzhou ACEA Pharmaceutical Research Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-17
- **Primary completion:** 2019-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060850, "A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03060850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*